The New Molecular Entity Evolocumab, One Kind of PCSK9 Inhibitor, Reduce Plasma Small Size LDL-Cholesterol Levels by Using a New Standardized Method of Measuring LDL Size
Open Access
- 1 January 2017
- journal article
- research article
- Published by Scientific Research Publishing, Inc. in Open Journal of Molecular and Integrative Physiology
- Vol. 07 (01), 1-23
- https://doi.org/10.4236/ojmip.2017.71001
Abstract
Aims: There has been no evidence on the effects of evolocumab, protein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, on small size LDL. We observationally investigated the efficacy and side effects of evolocumab on the LDL subfraction particle diameter using PAGE system for lipoprotein analysis. Methods: We defined 30 patients with high-risk hyperlipidemia. As for analysis of LDL subfraction profile, we used polyacrylamide gel electrophoresis three methods: 1) 3% nondenatured poly-acrylamide gel electrophoresis method (3%PAGE), 2) 2% - 16% nondenatured poly-acrylamide gradient gel electro-phoresis method (2% - 16% GGE) and 3) 2.7% - 5% GGE. Evolocumab 140 mg/day administered together with statin significantly improved serum total cholesterol (TC), triglyceride (TG), high-dense lipoprotein-cholesterol (HDL-C), and LDL-C after four-week treatment. Results: TC, TG, HDL-C and LDL-C levels were improved by, respectively, 33%, 20%, 10%, and 54%. The mean LDL size significantly increased from 25.6 ± 0.4 nm to 26.4 ± 0.8 nm. The small dense LDL-cholesterol (sdLDL-C), large buoyant LDL-cholesterol (lbLDL-C), and mid-band lipoprotein-cholesterol were reduced, respectively. Therefore, the preliminary study on this paper can be the first step into a new insight on the world of lipid metabolism. Conclusion: Short-term administration of evolocumab addedons to statin therapy, significantly reduced small size LDL levels.Keywords
This publication has 32 references indexed in Scilit:
- Rosuvastatin Reduces Plasma Small Dense Ldl-Cholesterol Predominantly in Non-Diabetic Hypercholesterolemic PatientsPharmacology & Pharmacy, 2012
- Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose TissueArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Direct and Simple Fluorescence Detection Method for Oxidized LipoproteinsAnalytical Chemistry, 2009
- Development of a Homogeneous Assay to Measure Remnant Lipoprotein CholesterolClinical Chemistry, 2007
- Disparate LDL Phenotypic Classification among 4 Different Methods Assessing LDL Particle CharacteristicsClinical Chemistry, 2006
- Are Measurements of LDL Particles Ready for Prime Time?Clinical Chemistry, 2006
- Treatment of Small Dense LDLJournal of Atherosclerosis and Thrombosis, 2002
- Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer diseaseNature Genetics, 1994
- Metabolism of VLDL and LDL subclassesCurrent Opinion in Lipidology, 1994
- The investigation of “mid-band” lipoproteins using polyacrylamide gel electrophoresisClinica Chimica Acta; International Journal of Clinical Chemistry, 1974